Burzynski Research Institute, Inc. (BZYR) - Strategic SWOT Analysis Review
- provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.
Business description – A detailed description of the company’s operations and business divisions.
Corporate strategy – GlobalData’s summarization of the company’s business strategy.
SWOT analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history – Progression of key events associated with the company.
Major products and services – A list of major products, services and brands of the company.
Key competitors – A list of key competitors to the company.
Key employees – A list of the key executives of the company.
Executive biographies – A brief summary of the executives’ employment history.
Key operational heads – A list of personnel heading key departments/functions.
Important locations and subsidiaries – A list of key locations and subsidiaries of the company, including contact details.
Key manufacturing facilities – A list of key manufacturing facilities of the company.
Burzynski Research Institute, Inc. (BRI) is a research based biopharmaceutical company. It carries out the identification, production, marketing, and sale of certain medical chemical compounds composed of growth-inhibiting peptides, amino acid derivatives and organic acids. The company offers these compounds under the trade name Antineoplastons. BRI's product portfolio consists of Antineoplastons, namely, A10 and AS2-1, being evaluated in Phase II clinical trial for the treatment of cancer. It also examines pharmacokinetics and pharmacodynamics of Antineoplastons in patients with neoplastic disease, and offers consulting services. The company has a research facility in Stafford, Texas. BRI is headquartered in Houston, Texas, the US.
Burzynski Research Institute, Inc. Key Recent Developments
Oct 26, 2015: Burzynski Research Institute Announces Publications Documenting Long-term Survival in Malignant Brain Tumors Following Antineoplaston Therapy Mar 26, 2015: Burzynski Research Institute Announces Publication of Phase 2 Clinical Study in Metastatic Colon Adenocarcinoma of the Liver
Reasons to Buy
Gain key insights into the company for academic or business research purposes. Key elements such as SWOT analysis and corporate strategy are incorporated in the profile to assist your academic or business research needs.
Identify potential customers and suppliers with this report’s analysis of the company’s business structure, operations, major products and services and business strategy.
Understand and respond to your competitors’ business structure and strategies with GlobalData’s detailed SWOT analysis. In this, the company’s core strengths, weaknesses, opportunities and threats are analyzed, providing you with an up to date objective view of the company.
Examine potential investment and acquisition targets with this report’s detailed insight into the company’s strategic, business and operational performance.
Note: Some sections may be missing if data is unavailable for the company.